CompletedPhase 4

Haloperidol for the Treatment of Nausea and Vomiting in the ED

United States60 participantsStarted 2021-04-01

Plain-language summary

Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * presenting to the emergency department with chief complaint of nausea or vomiting Exclusion Criteria: * abnormal blood pressure (\>200/100mmHg or \<90/40mmHg), * fever (\>100.4F), * acute trauma, * QT \> 450ms on cardiac monitor, * altered mental status (GCS \< 15), * chest pain, * known allergy to haloperidol or ondansetron, * Parkinson's disease, * pregnancy or lactation, * use of any antiemetic in the previous 8 hours, * nausea and vomiting associated with vertigo, * prisoners or any wards of the state.

What they're measuring

Visual Analog Scale (VAS)

Timeframe: from enrollment to 30, 60, and 90 minutes after drug administration

Trial details

NCT IDNCT04764344

SponsorWestern Michigan University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-05-22

View on ClinicalTrials.gov More Vomiting trials